Cargando…
Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study
BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190820/ https://www.ncbi.nlm.nih.gov/pubmed/30349380 http://dx.doi.org/10.2147/CMAR.S175286 |
_version_ | 1783363628471156736 |
---|---|
author | Niu, Quan Lu, Youyi Xu, Shigao Shi, Qun Guo, Baoyu Guo, Zhe Huang, Tianbao Wu, Yinxia Yu, Junjie |
author_facet | Niu, Quan Lu, Youyi Xu, Shigao Shi, Qun Guo, Baoyu Guo, Zhe Huang, Tianbao Wu, Yinxia Yu, Junjie |
author_sort | Niu, Quan |
collection | PubMed |
description | BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Kaplan–Meier analysis with log-rank test was used for survival comparisons. Multivariate Cox regression model was employed to analyze the effect of different treatments on overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 910 patients were identified between 2004 and 2014. Overall, 648 (71.2%) patients had small cell neuroendocrine carcinoma (SCNEC), 35 (3.8%) had large cell neuroendocrine carcinoma (LCNEC), 10 (1.1%) had carcinoid tumor (well-differentiated neuroendocrine tumor), 16 (1.8%) had paraganglioma/pheochromocytoma (PGL/PHEO), 619 (68.0%) had a poorly differentiated or undifferentiated histology grade, 214 (23.5%) presented with metastatic disease, 586 (64.4%) underwent transurethral ablation/destruction for bladder tumor, and 245 (26.9%) had partial/total cystectomy. Cystectomy+chemotherapy+radiotherapy (CCR) has the highest long-term survival rate among various treatments. The 1-, 3-, and 5-years CSS of CCR were 56%, 56%, and 56%, respectively. By using multivariable Cox proportional hazard model, age, histology, N stage, SEER stage, tumor size, radiotherapy, chemotherapy, and local treatment of the primary site were identified as independent predictors for OS and CSS; all P<0.05. CONCLUSION: In BNEC, SCNEC has an absolute advantage in number. SCNEC/LCNEC tend to be older men. PGL/PHEO and carcinoid tumors have younger mean ages, earlier tumor stages, and better prognosis than SCNEC/LCNEC. Surgery, radiotherapy and chemotherapy are better than conservative treatment. However, whatever cystectomy or bladder sparing, chemotherapy should be a major component of treatment. |
format | Online Article Text |
id | pubmed-6190820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-61908202018-10-22 Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study Niu, Quan Lu, Youyi Xu, Shigao Shi, Qun Guo, Baoyu Guo, Zhe Huang, Tianbao Wu, Yinxia Yu, Junjie Cancer Manag Res Original Research BACKGROUND: Bladder neuroendocrine carcinomas (BNECs) are relatively a rare type of tumor. The aim of this study was to examine the clinicopathological characteristics and predictors of survival outcomes of patients with BNECs based on the analysis of the national Surveillance, Epidemiology, and End Results (SEER) database. MATERIALS AND METHODS: Kaplan–Meier analysis with log-rank test was used for survival comparisons. Multivariate Cox regression model was employed to analyze the effect of different treatments on overall survival (OS) and cancer-specific survival (CSS). RESULTS: A total of 910 patients were identified between 2004 and 2014. Overall, 648 (71.2%) patients had small cell neuroendocrine carcinoma (SCNEC), 35 (3.8%) had large cell neuroendocrine carcinoma (LCNEC), 10 (1.1%) had carcinoid tumor (well-differentiated neuroendocrine tumor), 16 (1.8%) had paraganglioma/pheochromocytoma (PGL/PHEO), 619 (68.0%) had a poorly differentiated or undifferentiated histology grade, 214 (23.5%) presented with metastatic disease, 586 (64.4%) underwent transurethral ablation/destruction for bladder tumor, and 245 (26.9%) had partial/total cystectomy. Cystectomy+chemotherapy+radiotherapy (CCR) has the highest long-term survival rate among various treatments. The 1-, 3-, and 5-years CSS of CCR were 56%, 56%, and 56%, respectively. By using multivariable Cox proportional hazard model, age, histology, N stage, SEER stage, tumor size, radiotherapy, chemotherapy, and local treatment of the primary site were identified as independent predictors for OS and CSS; all P<0.05. CONCLUSION: In BNEC, SCNEC has an absolute advantage in number. SCNEC/LCNEC tend to be older men. PGL/PHEO and carcinoid tumors have younger mean ages, earlier tumor stages, and better prognosis than SCNEC/LCNEC. Surgery, radiotherapy and chemotherapy are better than conservative treatment. However, whatever cystectomy or bladder sparing, chemotherapy should be a major component of treatment. Dove Medical Press 2018-10-11 /pmc/articles/PMC6190820/ /pubmed/30349380 http://dx.doi.org/10.2147/CMAR.S175286 Text en © 2018 Niu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Niu, Quan Lu, Youyi Xu, Shigao Shi, Qun Guo, Baoyu Guo, Zhe Huang, Tianbao Wu, Yinxia Yu, Junjie Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title | Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title_full | Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title_fullStr | Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title_full_unstemmed | Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title_short | Clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
title_sort | clinicopathological characteristics and survival outcomes of bladder neuroendocrine carcinomas: a population-based study |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6190820/ https://www.ncbi.nlm.nih.gov/pubmed/30349380 http://dx.doi.org/10.2147/CMAR.S175286 |
work_keys_str_mv | AT niuquan clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT luyouyi clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT xushigao clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT shiqun clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT guobaoyu clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT guozhe clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT huangtianbao clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT wuyinxia clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy AT yujunjie clinicopathologicalcharacteristicsandsurvivaloutcomesofbladderneuroendocrinecarcinomasapopulationbasedstudy |